These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
525 related articles for article (PubMed ID: 17478762)
21. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315 [TBL] [Abstract][Full Text] [Related]
22. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients]. Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632 [TBL] [Abstract][Full Text] [Related]
23. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046 [TBL] [Abstract][Full Text] [Related]
24. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452 [TBL] [Abstract][Full Text] [Related]
25. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096 [TBL] [Abstract][Full Text] [Related]
26. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Park SS; Kim SW Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359 [TBL] [Abstract][Full Text] [Related]
27. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. Harłoziñska A; Bar JK; Wenderski R; Bebenek M In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803 [TBL] [Abstract][Full Text] [Related]
28. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer]. Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771 [TBL] [Abstract][Full Text] [Related]
29. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695 [TBL] [Abstract][Full Text] [Related]
30. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma]. Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937 [TBL] [Abstract][Full Text] [Related]
31. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of c-erbB2 expression in breast cancer. Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778 [TBL] [Abstract][Full Text] [Related]
33. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346 [TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors]. Zhang Z; Xu G; Liu S Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761 [TBL] [Abstract][Full Text] [Related]
35. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273 [TBL] [Abstract][Full Text] [Related]
36. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641 [TBL] [Abstract][Full Text] [Related]
37. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study. Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946 [TBL] [Abstract][Full Text] [Related]
38. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of p53 expression in primary breast carcinomas. Naidu R; Yadav M; Nair S; Kutty KK Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]